



Pergamon

Bioorganic & Medicinal Chemistry Letters 12 (2002) 2643–2646

BIOORGANIC &
MEDICINAL
CHEMISTRY
LETTERS

The Synthesis of Substituted Fluorenes as Novel Non-Imidazole Histamine H₃ Inhibitors

Pauline C. Ting,* Joe F. Lee, Margaret M. Albanese, Wing C. Tom, Daniel M. Solomon, Robert Aslanian, Neng-Yang Shih and Robert West

The Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA

Received 15 April 2002; accepted 10 June 2002


Abstract—A novel non-imidazole fluorene oxime **1a** has been identified as a histamine H₃ inhibitor, and its structure–activity relationship has been evaluated. © 2002 Elsevier Science Ltd. All rights reserved.

While the roles of H₁ receptor antagonists in the treatment of allergy and H₂ receptor antagonists in the treatment of gastric ulcers are well known, a pharmacological role for H₃ receptor antagonists has not yet been well delineated since its initial discovery in 1983.^{1–3} The H₃ receptor is present in highest concentrations in the brain and may therefore be useful for central nervous system disorders such as attention-deficit disorder, Alzheimer's disease, narcolepsy, epilepsy, or schizophrenia. However, the H₃ receptor is also present in the peripheral nervous system, and recent research indicates that a combination of an H₁ antagonist with an H₃ antagonist may be useful in the treatment of nasal congestion associated with allergic rhinitis, which is not treated by an H₁ antagonist alone.⁴ Allergic rhinitis affects over 20% of the US population and can result in sinusitis, otitis media, or nasal polyps. Current therapies for the treatment of congestion include oral decongestants such as pseudoephedrine, topical decongestants such as oxymetazoline, and nasal steroids all of which are known to have side effects such as hypertension, agitation, or insomnia.⁴

During a nasal allergic reaction, H₁ antihistamines minimize the plasma extravasation and mucus secretion caused by the release of histamine from mast cells. An H₃ antagonist, when used in conjunction with an H₁ antagonist, promotes decongestion by increasing vaso-

constriction and blood flow by restoring the release of the neurotransmitter norepinephrine, an endogenous decongestant, which is reduced by histamine activation of the H₃ receptor. This decongestive effect is not observed for an H₃ antagonist alone. This hypothesis has been verified in a histamine-driven cat model of nasal congestion.⁵ Our goal is to discover a novel, selective H₃ antagonist that can be used in combination with an H₁ antihistamine to relieve the nasal congestion associated with seasonal or perennial allergic rhinitis.

The first potent H₃ agonist and antagonist have been reported by Arrang and coworkers in 1987.⁶ A qualitative model describing receptor-inhibitor binding for the H₃ receptor has been proposed by Timmerman and coworkers.^{7,8} It is based on two hydrogen binding interactions between the receptor and an imidazole based inhibitor: one to the imidazole ring and one to a basic nitrogen in the side chain. The imidazole ring is considered important for biological activity, but the class of non-imidazole H₃ receptor ligands is expanding.^{9–12} We have found the imidazole ring to be a liability in terms of liver enzyme inhibition and decided to focus our research efforts on a non-imidazole lead structure. Biological screening, using our in vitro H₃ receptor binding assay,¹³ of our internal compound database identified compound **1a** as a novel H₃ receptor ligand.




*Corresponding author. Tel.: +1-908-740-3543; fax: +1-908-740-7305; e-mail: pauline.ting@spcorp.com


Compound **1a** has two possible hydrogen binding sites to fit the Timmerman model: the key oxime substituent and the dimethylamine side chain. Stark and coworkers have previously reported imidazole-based H₃ antagonists which contain an oxime moiety.¹⁴ In this communication, we describe a series of analogues which study the SAR relationship of **1a**.

Analogues **1a–h** that have diverse substituents replacing the dimethylaminoethyl side chain were prepared by alkylation of commercially available 2-hydroxy-9-fluorenone **4** followed by oxime formation (1:1 *E:Z* isomer mixture) as shown for the piperidinoethyl compound **1c** in Scheme 1.¹⁵ Further derivization of oxime **1c** with potassium bis(trimethylsilyl)amide as the base and the appropriate alkylating reagent yielded analogues **3d** and **3e**.


To replace the oxime moiety with a substituted nitrogen analogue, raney nickel reduction of oxime **1c** afforded amine **5** (Scheme 1). Amine **5** was not stable as the free base, and was stored and used as its hydrochloride salt. Acetylation of **5** produced amide **2g**, mesylation of **5** produced sulfonamide **2h**, and methylation of **5** produced amine **2e**.



The semicarbazone analogue **3f** was prepared by condensation of ketone **3a** with semicarbazide. Another nitrogen analogue, the morpholine compound **2f**, was prepared from ketone **6** by the following straightforward synthesis.




Scheme 1. (a) NaH, EtOH, 1-(2-chloroethyl)piperidine, Δ , 100%; (b) $\text{NH}_2\text{OH}\cdot\text{HCl}$, pyridine, 89%; (c) H_2 , RaNi , EtOH; (d) HCl/EtOH 86% for steps c and d; (e) AcCl , Et_3N , CH_2Cl_2 , 50% for **2g**; (f) MeSO_2Cl , Et_3N , CH_2Cl_2 , 40% for **2h**; (g) HCHO , HCOOH , Δ , 46% for **2e**.




To replace the oxime moiety with a substituted oxygen analogue, ketone **3a** was reduced with sodium borohydride to give alcohol **2b** (Scheme 2). Acetylation of alcohol **2b** provided ester **2c** while addition to isopropylisocyanate provided carbamate **2d**.

To replace the oxime moiety with a substituted carbon analogue, acetate **2c** was hydrogenated to yield **2a**.¹⁶ Formation of the anion of **2a** with *n*-butyl lithium and trapping with formaldehyde gave alcohol **2j**.¹⁷ The anion was also trapped with carbon dioxide (solid dry ice powder) to afford acid **2k**.¹⁸ Standard DEC coupling protocol converted acid **2k** to amide **2l**. Olefinic analogues were synthesized by a Wadsworth-Emmons reaction on ketone **3a** to provide the unsaturated ester **3g** (Scheme 3). Basic hydrolysis of **3g** and amide formation produced **3h**.

The biological activity of our side chain analogues **1a–h** are summarized in Table 1. Extension of the two carbon linker to a three carbon linker in **1b** retains H₃ activity. The dimethylamino group can be replaced with a cyclic piperidine **1c** or pyrrolidine **1d** and maintain H₃ potency indicating that there is some steric space available



Scheme 2. (a) NaBH₄, EtOH, 100%; (b) AcCl, Et₃N, DMAP, CH₂Cl₂, 100%; (c) H₂, Pd/C, EtOH, 82%; (d) *n*-BuLi, THF, 0°C, HCHO, 51%; (e) *n*-BuLi, THF, 0°C, CO₂, 31%; (f) DEC, HOBT, MeNH₂ in THF, CH₂Cl₂, 30%.



Scheme 3. (a) $(\text{MeO})_2\text{POCH}_2\text{COOMe}$, NaH, DMF, 83%; (b) NaOH, THF, MeOH, H_2O , 90%; (c) DEC, HOBT, MeNH_2 in THF, CH_2Cl_2 , 82%.

around the binding site of this nitrogen atom. In contrast, the morpholine analogue **1e** shows a decrease in biological activity. The spacial position of this nitrogen atom relative to the fluorene ring is important since the more constrained cyclic analogues **1f–h** are less active.

The analogues **2a–l** in Table 2 focus on the SAR of the oxime moiety with the side chain fixed as the piperidinoethyl ether. As the data indicates, the SAR of this position is very restrictive. Removal of the oxime moiety results in the inactive saturated analogue **2a**. Replacement of the oxime with a hydroxy group as in **2b** decreases H_3 activity slightly, and additional substitution as the acetate **2c** or the carbamate **2d** is even more

Table 1. In vitro H_3 activity of fluorene oximes **1a–h**

| Example No. | R^a | K_i (nM) ^b |
|-------------|--------------|-------------------------|
| 1a | | 40 |
| 1b | | 48 |
| 1c | | 45 |
| 1d | | 65 |
| 1e | | 325 |
| 1f | | 920 |
| 1g | | 310 |
| 1h | | 110 |

^aCompounds are a mixture of *E* and *Z* isomers.

^b K_i values are the average of at least two independent determinations.

Table 2. In vitro H_3 activity of fluorenes **2a–l**

| Example No. | R | K_i (nM) ^a |
|-------------|----------------------|-------------------------|
| 2a | H | 20% ^b |
| 2b | OH | 190 |
| 2c | OAc | 40% ^b |
| 2d | OCNH <i>i</i> Pr | 20% ^b |
| 2e | NMe ₂ | 650 |
| 2f | Morpholine | 15% ^b |
| 2g | NHAc | 27% ^b |
| 2h | NHSO ₂ Me | 13% ^b |
| 2i | NHCONH <i>i</i> Pr | 17% ^b |
| 2j | CH ₂ OH | 570 |
| 2k | COOH | 39% ^b |
| 2l | CONHMe | 19% ^b |

^a K_i values are the average of at least two independent determinations.

detrimental. Similarly, replacement of the oxime with a dimethylamino group as in **2e** reduces H_3 activity, and various nitrogen analogues **2f–i** are completely inactive. Several carbon analogues **2j–l** were synthesized, and only the hydroxymethyl compound **2j** shows some weak H_3 activity.

Due to the poor biological activity observed with analogues **2a–l**, we decided that the sp^2 hybridization of the oxime must be important for achieving H_3 potency. The oxime isomers of **1c** were separated by preparative thin layer chromatography to give the *E* isomer **3b** and the *Z* isomer **3c**, and the biological activity resides in the *Z* isomer **3c** (Table 3). Ketone **3a** shows reduced activity as do the substituted oxime analogues **3d** and **3e** and the substituted hydrazine analogue **3f**. Even the simple methyl oxime **7** is inactive and indicates that the hydrogen bonding characteristic of the oxime is important for binding. The alkene analogues **3g** and **3h** also exhibit no H_3 activity. Therefore, the oxime substituent is unique in its small size and directionality of hydrogen binding capability to impart potent H_3 activity.


Table 3. In vitro H_3 activity of fluorenes **3a–h**

| Example No. | R^a | K_i (nM) ^b |
|-------------|--------------------------------------|-------------------------|
| 3a | O | 47% ^c |
| 1c | NOH | 45 |
| 3b | NOH (<i>E</i>) | 690 |
| 3c | NOH (<i>Z</i>) | 65 |
| 3d | NOCH ₂ CN | 24% ^c |
| 3e | NOCH ₂ CH ₂ OH | 24% ^c |
| 3f | NNHCONH ₂ | 27% ^c |
| 3g | CHCOOMe | 20% ^c |
| 3h | CHCONHMe | 20% ^c |

^aCompounds are a mixture of *E* and *Z* isomers unless otherwise noted.

^b K_i values are the average of at least two independent determinations.

^c% Inhibition at 1 $\mu\text{g/mL}$.



In conclusion, SAR studies based on the lead structure **1a** have led to identification of other analogues in this series with equivalent binding potency, although none demonstrated an improved profile. Nevertheless, the identification of this novel non-imidazole series of H₃ inhibitors has encouraged our search for other possible non-imidazole lead structures. Additional studies will be reported in future publications.

Acknowledgements

The authors would like to thank Ms. Susan She and Ms. Shirley Williams for conducting the H₃ receptor binding assay.

References and Notes

1. Arrang, J.-M.; Garbarg, M.; Schwartz, J.-C. *Nature* **1983**, *302*, 832.
2. Leurs, R.; Blandina, P.; Tedford, C.; Timmerman, H. *Trends Pharm. Sci.* **1998**, *19*, 177.
3. Tozer, M. J.; Kalindjian, S. B. *Exp. Opin. Ther. Patents* **2000**, *10*, 1045.
4. McLeod, R. L.; Egan, R. W.; Cuss, F. M.; Bolser, D. C.; Hey, J. A. In *Progress in Respiratory Research*; Hansel, T. T., Barnes, P. J., Eds.; Karger: Basel, 2001; Vol. 31, pp 133–136.
5. McLeod, R. L.; Mingo, G. G.; Herczku, C.; DeGennaro-Culver, F.; Kreutner, W.; Egan, R. W.; Hey, J. A. *Am. J. Rhinol.* **1999**, *13*, 391.
6. Arrang, J.-M.; Garbarg, M.; Lancelot, J.-C.; Lecomte, J.-M.; Pollard, H.; Robba, M.; Schunack, W.; Schwartz, J.-C. *Nature* **1987**, *327*, 117.
7. De Esch, I. J. P.; Timmerman, H.; Menge, W. M. P. B.; Nederkoorn, P. H. J. *Arch. Pharm. Pharm. Med. Chem.* **2000**, *333*, 254.
8. De Esch, I. J. P.; Mills, J. E. J.; Perkins, T. D. J.; Romeo, G.; Hoffmann, M.; Wieland, K.; Leurs, R.; Menge, W. M. P. B.; Nederkoorn, P. H. J.; Dean, P. M.; Timmerman, H. *J. Med. Chem.* **2001**, *44*, 1666.
9. Linney, I. D.; Buck, I. M.; Harper, E. A.; Kalindjian, S. B.; Pether, M. J.; Shankley, N. P.; Watt, G. F.; Wright, P. T. *J. Med. Chem.* **2000**, *43*, 2362.
10. Meier, G.; Apelt, J.; Reichert, U.; Graßmann, S.; Ligneau, X.; Elz, S.; Leurquin, F.; Ganellin, C. R.; Schwartz, J. C.; Schunack, W.; Stark, H. *Eur. J. Pharm. Sci.* **2001**, *13*, 249.
11. Bennani, Y. L.; Black, L. A.; Dwight, W. J.; Faghih, R.; Gentles, R. G.; Liu, H.; Phelan, K. M.; Vasudevan, A.; Zhang, H. Q. World Patent 01/66534 A2, 2001; *Chem. Abst.* **2001**, *135*, 242249.
12. Breitenbucher, J. G.; Chai, W. World Patent 01/74773 A2, 2001; *Chem. Abst.* **2001**, *135*, 288691.
13. Korte, A.; Myers, J.; Shih, N. Y.; Egan, R. W.; Clark, M. A. *Biochem. Biophys. Res. Commun.* **1990**, *168*, 979.
14. Sasse, A.; Sadek, B.; Ligneau, X.; Elz, S.; Pertz, H. H.; Luger, P.; Ganellin, C. R.; Arrang, J.-M.; Schwartz, J.-C.; Schunack, W.; Stark, H. *J. Med. Chem.* **2000**, *43*, 3335.
15. All synthesized target analogues were fully characterized by ¹H NMR, ¹³C NMR, and high-resolution mass spectroscopy.
16. Streitweiser, A.; Brown, S. M. *J. Org. Chem.* **1988**, *53*, 904.
17. Chong, J. M.; Lajoie, G.; Tjepkema, M. W. *Synthesis* **1992**, 819.
18. Bavin, P. M. G. *Anal. Chem.* **1960**, *32*, 554.